C2CD4C

Across TCGA pan-cancer cohorts, C2CD4C RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated C2CD4C data layer compared with 2 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher C2CD4C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated C2CD4C expression acts as an unfavorable survival marker, although some lineages such as KIRC and SCLC show a favorable association.

MESO, KIRC, and UVM are the cancer types where C2CD4C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.265	0.532	<.001	109	view →
KIRC	OS	Median	All	0.854	0.754	<.001	85	view →
UVM	DFS	Tertile	III,IV	0.183	1.000	.001	72	view →
ACC	DFS	Tertile	All	0.321	0.790	.002	67	view →
SCLC	OS	Tertile	All	0.774	0.481	.004	35	view →
KIRP	DFS	Quartile	III,IV	0.372	0.743	.003	33	view →
UCS	OS	Tertile	IV	0.205	1.000	.024	30	view →
THYM	DFS	Median	II,III,IV	1.000	0.645	<.001	30	view →
HNSC	DFS	Median	IV	0.703	0.579	.011	23	view →
BRCA	OS	Median	III,IV	0.899	0.763	.001	22	view →
LIHC	OS	Tertile	II,III,IV	0.728	0.374	.004	17	view →
PRAD	DFS	Tertile	All	0.737	0.913	.005	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

C2CD4C–MESO (OS)

Open the MESO breakdown →